Disc Medicine (IRON) – Investment Analysts’ Recent Ratings Updates

Disc Medicine (NASDAQ: IRON) has recently received a number of price target changes and ratings updates:

• 9/2/2026 – Disc Medicine had its price target raised by Wedbush from $88.00 to $100.00. They now have an “outperform” rating on the stock.
• 9/1/2026 – Disc Medicine had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/29/2026 – Disc Medicine was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/17/2026 – Disc Medicine had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $90.00 price target on the stock.
• 8/6/2026 – Disc Medicine had its price target raised by HC Wainwright from $118.00 to $120.00. They now have a “buy” rating on the stock.
• 8/1/2026 – Disc Medicine was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/17/2026 – Disc Medicine had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, CEO John Quisel sold 33,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $17,892,965.60. This represents a 12.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kevin Bitterman sold 5,203 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $79.98, for a total value of $416,135.94. Following the transaction, the director owned 13,445 shares of the company’s stock, valued at $1,075,331.10. This trade represents a 27.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 208,108 shares of company stock worth $15,799,739. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.